The new generic versions of both hepatitis C drugs will cost $24,000 for a course of treatment. When Harvoni was introduced to the market in 2014, it was priced at $94,500 a treatment. Epclusa came to the market in 2016 with a list price of $74,760.
Gilead’s generic versions of Epclusa and Harvoni will be launched in Januarythrough a newly created subsidiary, Asegua Therapeutics. The drugs are known as authorized generics, which are cheaper versions of brand-name drugs sold by the original manufacturer.
The brand-name hepatitis C drugs, which cures patients of the illness, remain two of the best-selling pharmaceutical products in history, and helped boost Gilead to a market valuation of nearly $100 billion. However, the hefty price of the drugs also made Gilead the subject of public criticism, with many accusing the pharma giant of greed.
More articles on pharmacy:
PBM lobby selects new chief with government ties: 5 things to know
AbbVie hit with lawsuit over alleged $1.2B kickback scheme
Reputation save: Novartis links employee bonuses to ethical behavior
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
